ISTERIAN Trademark

Trademark Overview

On Tuesday, December 6, 2022, a trademark application was filed for ISTERIAN with the United States Patent and Trademark Office. The USPTO has given the ISTERIAN trademark a serial number of 97705569. The federal status of this trademark filing is REGISTERED as of Tuesday, March 25, 2025. This trademark is owned by Cambrian BioPharma, Inc.. The ISTERIAN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins; Research and development in the field of fibrosis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins
isterian

General Information

Serial Number97705569
Word MarkISTERIAN
Filing DateTuesday, December 6, 2022
Status700 - REGISTERED
Status DateTuesday, March 25, 2025
Registration Number7739812
Registration DateTuesday, March 25, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements

Goods and ServicesDrug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins; Research and development in the field of fibrosis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 4, 2023
Primary Code042
First Use Anywhere DateThursday, November 21, 2024
First Use In Commerce DateThursday, November 21, 2024

Trademark Owner History

Party NameCambrian BioPharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003
Party NameCambrian BioPharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10003
Party NameCambrian BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events

Event DateEvent Description
Friday, December 9, 2022NEW APPLICATION ENTERED
Wednesday, January 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 7, 2023ASSIGNED TO EXAMINER
Monday, July 10, 2023NON-FINAL ACTION WRITTEN
Monday, July 10, 2023NON-FINAL ACTION E-MAILED
Monday, July 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 5, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 29, 2023NON-FINAL ACTION WRITTEN
Wednesday, November 29, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 29, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 29, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 29, 2023NON-FINAL ACTION E-MAILED
Wednesday, November 29, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 27, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, April 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, February 20, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 21, 2025STATEMENT OF USE PROCESSING COMPLETE
Monday, December 9, 2024USE AMENDMENT FILED
Monday, December 9, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, March 5, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, March 5, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, March 25, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, March 25, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

isterian development research field pharmaceutical extracellular matrix proteins scientific purposes medical